Objective:To investigate the effects of fibroblast growth factor receptor 1(FGFR1)on the resistance of colorectal cancer(CRC)cells to oxaliplatin(OXA).Methods:An OXA-resistant cell line(HCT8/OXA)was established by treating HCT8 CRC cells with low-dose OXA for a long period in vitro.The CCK-8 assay was used to compare the viability of the HCT8 and HCT8/OXA cells after OXA treatment and to exam-ine their resistance to the anticancer drug.Second-generation high-throughput sequencing technology was used to identify differentially ex-pressed genes between the parental and drug-resistant cells.The expression of FGFR1 in the HCT8 and HCT8/OXA cells was detected by Western blot assay.Colony formation and flow cytometric assays were used to determine cell proliferation and apoptosis,respectively.The expression of PI3K/AKT signaling pathway-related proteins was detected using Western blot assay.Results:Compared with the levels in the HCT8 cells,the FGFR1 levels were significantly increased in the HCT8/OXA cells(P<0.01).FGFR1 overexpression in the HCT8 cells increased their drug resistance(P<0.01)and proliferation(NC+OXA:236.67±6.24;FGFR1+OXA:568.33±6.24)and decreased their apoptotic rate after OXA treatment(NC+OXA:27.83±0.85;FGFR1+OXA:17.47±1.25).FGFR1 knockdown in the HCT8/OXA cells reduced their drug resistance(P<0.01)and proliferative ability(Si-NC+OXA:411±8.29;Si-FGFR1+OXA:233.33±20.55)and increased their apoptotic rate(Si-NC+OXA:2.85±0.17;Si-FGFR1+OXA:14.42±0.77).FGFR1 inhibited the activity of the PI3K/AKT signaling pathway and cell apoptosis and improved the proliferation and drug resistance of the CRC cells.By contrast,an activator of the PI3K/AKT pathway blocked the effects of FGFR1 on this sig-naling pathway and drug resistance in the CRC cells.Conclusions:FGFR1 can inhibit the PI3K/AKT signaling pathway and thereby reduce the sensitivity of CRC cells to OXA.

Objective:To investigate the effects of fibroblast growth factor receptor 1(FGFR1)on the resistance of colorectal cancer(CRC)cells to oxaliplatin(OXA).Methods:An OXA-resistant cell line(HCT8/OXA)was established by treating HCT8 CRC cells with low-dose OXA for a long period in vitro.The CCK-8 assay was used to compare the viability of the HCT8 and HCT8/OXA cells after OXA treatment and to exam-ine their resistance to the anticancer drug.Second-generation high-throughput sequencing technology was used to identify differentially ex-pressed genes between the parental and drug-resistant cells.The expression of FGFR1 in the HCT8 and HCT8/OXA cells was detected by Western blot assay.Colony formation and flow cytometric assays were used to determine cell proliferation and apoptosis,respectively.The expression of PI3K/AKT signaling pathway-related proteins was detected using Western blot assay.Results:Compared with the levels in the HCT8 cells,the FGFR1 levels were significantly increased in the HCT8/OXA cells(P<0.01).FGFR1 overexpression in the HCT8 cells increased their drug resistance(P<0.01)and proliferation(NC+OXA:236.67±6.24;FGFR1+OXA:568.33±6.24)and decreased their apoptotic rate after OXA treatment(NC+OXA:27.83±0.85;FGFR1+OXA:17.47±1.25).FGFR1 knockdown in the HCT8/OXA cells reduced their drug resistance(P<0.01)and proliferative ability(Si-NC+OXA:411±8.29;Si-FGFR1+OXA:233.33±20.55)and increased their apoptotic rate(Si-NC+OXA:2.85±0.17;Si-FGFR1+OXA:14.42±0.77).FGFR1 inhibited the activity of the PI3K/AKT signaling pathway and cell apoptosis and improved the proliferation and drug resistance of the CRC cells.By contrast,an activator of the PI3K/AKT pathway blocked the effects of FGFR1 on this sig-naling pathway and drug resistance in the CRC cells.Conclusions:FGFR1 can inhibit the PI3K/AKT signaling pathway and thereby reduce the sensitivity of CRC cells to OXA.

Objective:To explore stereoscopic vision and its correlation with cognitive function in first-episode drug-na?ve patients diagnosed with schizophrenia (FNPS).Methods:A study was conducted from January 2019 to September 2020. A total of 146 FNPS, 124 patients with chronic schizophrenia (PCS) and 101 healthy controls (HCs) were recruited. Stereoscopic vision was evaluated by Titumus stereotests. Their clinical symptoms were assessed by positive and negative syndrome scale. Cognitive function was assessed by the repeatable battery for the assessment of neuropsychological status (RBANS). The differences in stereoscopic vision and cognitive function among the three groups were analyzed by analysis of covariance. The Spearman correlation and multiple regression analysis were used to identify the correlation between stereoscopic vision and clinical symptoms or cognitive function.Results:(1) There were significant differences in stereoscopic vision and cognitive function among the three groups ( P<0.05). After pairwise comparison, it was found that the stereoscopic vision and cognitive functions of FNPS group and PCS group were significantly different from HCs group. However, there were no significant differences in stereoscopic vision and cognitive function between FNPS and PCS groups. (2) Spearman correlation analysis showed that stereoscopic vision was not correlated with the severity of clinical symptoms in FNPS, but it was correlated with visuospatial score ( r=-0.193, P=0.019), language score ( r=-0.261, P=0.001), attention score ( r=-0.168, P=0.042), and RBANS total scores ( r=-0.236, P=0.004). Moreover, there was no correlation of stereoscopic vision with the severity of clinical symptoms or cognitive function in HCs and PCS. Further multiple linear regression showed the significant effect of stereoscopic vision on visuospatial score ( β=-0.213, P=0.011), language score ( β=-0.252, P=0.003), attention score ( β=-0.189, P=0.019), RBANS total score ( β=-0.235, P=0.003) in FNPS. Conclusions:FNPS and PCS show significant impairments in stereoscopic vision and cognitive function. Stereoscopic vision is closely correlated with cognitive function rather than the severity of clinical symptoms in FNPS.

Objective:To explore stereoscopic vision and its correlation with cognitive function in first-episode drug-na?ve patients diagnosed with schizophrenia (FNPS).Methods:A study was conducted from January 2019 to September 2020. A total of 146 FNPS, 124 patients with chronic schizophrenia (PCS) and 101 healthy controls (HCs) were recruited. Stereoscopic vision was evaluated by Titumus stereotests. Their clinical symptoms were assessed by positive and negative syndrome scale. Cognitive function was assessed by the repeatable battery for the assessment of neuropsychological status (RBANS). The differences in stereoscopic vision and cognitive function among the three groups were analyzed by analysis of covariance. The Spearman correlation and multiple regression analysis were used to identify the correlation between stereoscopic vision and clinical symptoms or cognitive function.Results:(1) There were significant differences in stereoscopic vision and cognitive function among the three groups ( P<0.05). After pairwise comparison, it was found that the stereoscopic vision and cognitive functions of FNPS group and PCS group were significantly different from HCs group. However, there were no significant differences in stereoscopic vision and cognitive function between FNPS and PCS groups. (2) Spearman correlation analysis showed that stereoscopic vision was not correlated with the severity of clinical symptoms in FNPS, but it was correlated with visuospatial score ( r=-0.193, P=0.019), language score ( r=-0.261, P=0.001), attention score ( r=-0.168, P=0.042), and RBANS total scores ( r=-0.236, P=0.004). Moreover, there was no correlation of stereoscopic vision with the severity of clinical symptoms or cognitive function in HCs and PCS. Further multiple linear regression showed the significant effect of stereoscopic vision on visuospatial score ( β=-0.213, P=0.011), language score ( β=-0.252, P=0.003), attention score ( β=-0.189, P=0.019), RBANS total score ( β=-0.235, P=0.003) in FNPS. Conclusions:FNPS and PCS show significant impairments in stereoscopic vision and cognitive function. Stereoscopic vision is closely correlated with cognitive function rather than the severity of clinical symptoms in FNPS.

Objective To compare the sensitivity and specificity of venereal disease research laboratory (VDRL) test versus several other laboratory tests in the diagnosis of neurosyphilis. Methods Lumber puncture was conducted to obtain cerebrospinal fluid (CSF) from untreated outpatients with latent syphilis (LS) or serofast outpatients with LS. Then, VDRL test, rapid plasma regain (RPR) test, Treponema pallidum particle agglutination (TPPA) assay, fluorescent treponemal antibody-absorption (FTA-ABS) test and protein quantification were performed on these CSF samples. The sensitivity, specificity, positive predictive value and negative predictive value were compared between VDRL test and four other laboratory tests in the diagnosis of neurosyphilis. Results Totally, 61 cases of latent syphilis were included in this study. The sensitivity, specificity,positive predictive value and negative predictive value were 93.44% (57/61), 99.32%(293/295), 96.61%(57/59), 98.65% (293/297)for CSF-RPR, respectively, 91.80% (56/61), 82.71% (244/295), 52.34% (56/107),97.99 (244/249) for CSF-TPPA, respectively, 93.44% (57/61), 82.71% (244/295), 52.78%(57/108), 98.39%(244/248) for CSF-FTA-ABS, respectively, and 49.18%(30/61), 97.29% (287/295), 78.95% (30/38),90.25% (287/318) for CSF protein quantification, respectively. Conclusions CSF-VDRL cannot be replaced by CSF-RPR, -TPPA, -FTA-ABS, or CSF protein quantification in the diagnosis of neurosyphilis. CSF-RPR shows a high sensitivity and specificity in the diagnosis of neurosyphilis, with an increased diagnostic capability (area under the receiver operating characteristic curve) compared with CSF-TPPA, CSF-FTA-ABS or CSF protein quantification.